17:57 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Antibody scaffolds Sialylation of immune complexes could enhance the response to HIV vaccines. Patients who spontaneously controlled HIV without therapy and patients who had evolved neutralizing activity against a panel of 11 HIV-1 viruses (neutralizers)...
17:56 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms; imaging

TECHNOLOGY: Structural analyses; other An electron microscopy-based method for identifying epitopes that elicit potent neutralizing antibodies could be used to guide the development of vaccines for infectious diseases. The method involves six steps: digesting animal- or...
18:33 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Patient sample and cell culture studies identified a neutralizing antibody against HIV gp120 that could help treat HIV/AIDS. Screening of peripheral blood B cells from a patient followed by testing of antibody...
19:11 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Gilead's TLR7 agonist shows promise against HIV in shock and kill combo in monkeys

Researchers showed that a broadly neutralizing antibody (bNAb) delayed HIV rebound in a "shock and kill" combination with toll-like receptor 7 (TLR7) agonist vesatolimod (GS-9620) from Gilead Sciences Inc. (NASDAQ:GILD) after discontinuation of antiretroviral therapy...
22:57 , Mar 5, 2018 |  BC Extra  |  Preclinical News

HIV shock and kill combo shows promise in monkeys

Researchers showed that a broadly neutralizing antibody (bNAb) delayed HIV rebound in a "shock and kill" combination with toll-like receptor 7 (TLR7) agonist vesatolimod (GS-9620) from Gilead Sciences Inc. (NASDAQ:GILD) after discontinuation of antiretroviral therapy...
19:40 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Non-human primate studies suggest a trispecific, broadly neutralizing antibody (bNAb) could help treat HIV. Screening of combinations of a panel of bNAbs in neutralization assays, followed by generation of bNAbs incorporating features of the...
00:01 , Sep 21, 2017 |  BC Extra  |  Preclinical News

NIAID, Sanofi develop trispecific bNAb for HIV

In a paper published in Science, researchers at NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and Sanofi (Euronext:SAN; NYSE:SNY) identified a trispecific broadly neutralizing antibody (bNAb) which conferred 100% protection against simian HIV...
15:44 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Mologen's lefitolimod misses in extension for HIV infection

Mologen AG (Xetra:MGN) reported data from 12 patients with chronic HIV-1 infection on antiretroviral therapy (ART) in a 24-week extension of the open-label, Danish Phase Ib/IIa TEACH trial showing that twice-weekly 60 mg subcutaneous lefitolimod...
23:03 , Aug 9, 2017 |  BC Extra  |  Clinical News

Mologen sinks on lefitolimod HIV miss

Mologen AG (Xetra:MGN) dropped €0.81 (21%) to €3.06 on Wednesday after its lefitolimod (MGN1703) missed the primary endpoint in an extension of the Phase Ib/IIa TEACH trial to treat HIV infection in patients on antiretroviral...
18:31 , Aug 9, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models Cows could be used to generate bNAbs against HIV. In four cows, immunization with an HIV env mimic elicited antibodies in all animals, one of which produced antibodies that neutralized 23 (20%) and...